Targeting the IKs Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants
Ling ZhongZhenzhen YanDexiang JiangKuo-Chan WengYue OuyangHangyu ZhangXiaoqing LinChenxin XiaoHuaiyu YangJing YaoXinjiang KangChanghe WangChen HuangBing ShenSookja Kim ChungZhi-Hong JiangWandi ZhuErwin NeherJonathan R. SilvaPanpan HouDr. Neher's Biophysics Laboratory for Innovative Drug Discovery,State Key Laboratory of Quality Research in Chinese Medicine,Macau University of Science and Technology,Taipa,Macao SAR,China (L.Z.,Z.Y.,D.J.,Y.O.,H.Z.,X.L.,C.X.,C.H.,B.S.,S.K.C.,Z.-H.J.,E.N.,P.H.).Macau University of Science and Technology Zhuhai MUST Science and Technology Research Institute. Zhuhai,Guangdong,China (L.Z.,Z.Y.,D.J.,Y.O.,H.Z.,X.L.,C.X.,C.H.,B.S.,S.K.C.,Z.-H.J.,E.N.,P.H.).Department of Biomedical Engineering,Center for the Investigation of Membrane Excitability Disorders,Cardiac Bioelectricity and Arrhythmia Center,Washington University,St. Louis,MO (K.-C.W.,J.R.S.).Shanghai Key Laboratory of Regulatory Biology,Institute of Biomedical Sciences and School of Life Sciences,East China Normal University (H.Y.).State Key Laboratory of Virology,Hubei Key Laboratory of Cell Homeostasis,College of Life Sciences,TaiKang Center for Life and Medical Sciences,Frontier Science Center for Immunology and Metabolism,Wuhan University,China (J.Y.).Key Laboratory of Medical Electrophysiology,Ministry of Education of China,Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease and the Institute of Cardiovascular Research,Southwest Medical University,Luzhou,China (X.K.).Department of Neurosurgery,the Affiliated Hospital of Southwest Medical University,Luzhou,China (X.K.).College of Life Sciences,Liaocheng University,China (X.K.).Department of Neurology,First Affiliated Hospital,Neuroscience Research Center,Key Laboratory of Biomedical Information Engineering of Ministry of Education,School of Life Science and Technology,Xi'an Jiaotong University,China (C.W.).Cardiovascular Medicine Division and Department of Medicine,Brigham and Women's Hospital,Harvard Medical School,Boston,MA (W.Z.).
DOI: https://doi.org/10.1161/circresaha.124.325009
IF: 23.213
2024-08-23
Circulation Research
Abstract:Circulation Research, Ahead of Print. BACKGROUND:The KCNQ1+KCNE1 (IKs) potassium channel plays a crucial role in cardiac adaptation to stress, in which β-adrenergic stimulation phosphorylates the IKschannel through the cyclic adenosine monophosphate (cAMP)/PKA (protein kinase A) pathway. Phosphorylation increases the channel current and accelerates repolarization to adapt to an increased heart rate. Variants in KCNQ1 can cause long-QT syndrome type 1 (LQT1), and those with defective cAMP effects predispose patients to the highest risk of cardiac arrest and sudden death. However, the molecular connection between IKschannel phosphorylation and channel function, as well as why high-risk LQT1 mutations lose cAMP sensitivity, remain unclear.METHODS:Regular patch clamp and voltage clamp fluorometry techniques were utilized to record pore opening and voltage sensor movement of wild-type and mutant KCNQ1/IKschannels. The clinical phenotypic penetrance of each LQT1 mutation was analyzed as a metric for assessing their clinical risk. The patient-specific–induced pluripotent stem-cell model was used to test mechanistic findings in physiological conditions.RESULTS:By systematically elucidating mechanisms of a series of LQT1 variants that lack cAMP sensitivity, we identified molecular determinants of IKschannel regulation by phosphorylation. These key residues are distributed across the N-terminus of KCNQ1 extending to the central pore region of IKs. We refer to this pattern as the IKschannel PKA phosphorylation axis. Next, by examining LQT1 variants from clinical databases containing 10 579 LQT1 carriers, we found that the distribution of the most high-penetrance LQT1 variants extends across the IKschannel PKA phosphorylation axis, demonstrating its clinical relevance. Furthermore, we found that a small molecule, ML277, which binds at the center of the phosphorylation axis, rescues the defective cAMP effects of multiple high-risk LQT1 variants. This finding was then tested in high-risk patient-specific induced pluripotent stem cell–derived cardiomyocytes, where ML277 remarkably alleviates the beating abnormalities.CONCLUSIONS:Our findings not only elucidate the molecular mechanism of PKA-dependent IKschannel phosphorylation but also provide an effective antiarrhythmic strategy for patients with high-risk LQT1 variants.
cardiac & cardiovascular systems,peripheral vascular disease,hematology